• Highly conscientious, results-orientated, hands-on scientist
• 17 years pharma experience specializing in continuous manufacturing of pharmaceuticals and early to late-stage solid dosage formulation development
• Leader of high-performing teams applying expertise in fundamental pharmaceutical scientific principles to rationally finding solutions to various formulation and process challenges resulting in viable and robust products

Ph.D. - Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, Utah.
Ph.D. dissertation title: The Internalization and Fate of HPMA Copolymers and Antisense-HPMA Copolymer Conjugates in Hep G2 Cells.
Ph.D. committee: Jindrich Kopecek (chair), William Higuchi, Sung Wan Kim, H. Steven Wiley, and Pavla Kopeckova
Grade Point Average (GPA): 3.93 / 4.00

Honors Bachelor of Science - University of Utah.
Thesis advisor: J. Calvin Giddings
Major: Chemistry
Minor: German
Graduated cum laude
GPA: 3.83 / 4.00

Study Abroad - Technische Universitaet Braunschweig, Braunschweig, Germany.
Intensive German language and culture program.
GPA: 4.00 / 4.00

Owner and Independent Pharmaceutical Consultant: Keith Jensen Consulting, 6/2017-present. Rockville, Maryland.

• Consulting on formulation and processing of oral and medical device/drug products
• World leader on thin film formulation and processing
• Expert on continuous manufacturing of pharmaceutical drug products
• Scientific advisor for pharmaceutical companies
• Expert witness in patent litigation

USP Expert Panel on Continuous Manufacturing: The United States Pharmacopeial Convention, 11/2016-present. Rockville, Maryland.

• Active member of the USP Quality Standards for Pharmaceutical Continuous Manufacturing Expert Panel
• Provide the USP with Continuous Manufacturing expertise
• Contribute to publications on Continuous Manufacturing Guidances
• Propose and promote research on Continuous Manufacturing
• Part of first group to propose chapters on Continuous Manufacturing in the USP

Advisory Board: Veramorph Materials, 8/2018-present. Rockville, Maryland.

At Veramorph Materials we are developing simple nano-crystal formulations to improve delivery of challenging drug molecules.

Associate Director / Principal Investigator: Novartis-MIT Center for Continuous Manufacturing, 02/2014-05/2017,
Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts.

• Led a team of 13 researchers (Staff Engineers, Post-doctoral Fellows, Graduate Students) and worked with more than half of the 12 professors and their research groups in the Novartis-MIT Center.
• 4 Invited talks, 5 Patent disclosures/applications, +8 Articles, 9 Posters
• Help manage Center finances (~$8.5 M/yr), my group's budget: ~$1.5 M/yr

• Four major projects: novel methods to continuously manufacture tablets in the most direct and simple path (minimize the number of unit operations for problematic drugs)


• Continuous heterogeneous crystallization of API on excipients
• Crystallize problematic drugs (e.g. needles, poor flowability, etc.) directly onto excipients so that the excipient controls the particle morphology and properties
• Simplifies filtration, drying, and is followed by direct compression
• 2 Patent applications filed


• Integrated hot-melt extrusion, injection molding, and mold coating of tablets
• Use HME to simplify formulation of problematic drugs
• HME is directly coupled to injection molding machine
• Tablets are injection molded (no powder compaction) from molten extrudate
• Molded tablets are then coated via coupled injection molding
• Patent application filed


• Tableting of electrospun mats containing API
• Drug containing mats are produced via free-surface electrospinning
• Mats are continuously and directly processed into tablets/caplets
• Patent disclosure in preparation


• Tableting of API containing thin films
• Drug containing thin films are produced via solvent casting and drying
• Film is folded and compressed into a tablet/caplet
• Patent disclosure in preparation


(Shortcuts to:) Four invited talks, five patents, +eight publications, and eight posters

Formulation Manager: LTS Lohmann Therapy Systems, West Caldwell, New Jersey, 2003-2014. +10 years solid dosage formulation experience (oral thin films e.g. strips) from early to late-stage formulation development.

Formulation Development

• Successfully developed and managed 9 major projects and 23 minor projects in 10 years (80% Rx, 20% OTC) culminating in 7 clinical studies (5 human, 1 canine, 1 hamster)
• Sourcing, evaluating, and selecting raw materials
• Applied scientific and technical expertise to overcome various API challenges (poor aqueous solubility, stability, first-pass effect) resulting in viable, robust formulations
• Utilized DOE's in formulation testing following QbD principles
• Wrote and executed stability study protocols following ICH guidelines
• Three exceptionally successful and four successful pharmacokinetics results
• Increased bioavailability of an API with very poor aqueous solubility from minimal to 70-75% (Global Patents Filed, Patent already granted in Germany and Panama)
• Project expanded to second compound in same chemical class with similar success
• Increased bioavailability of another API with both very poor aqueous solubility and severe first-pass effect (+98% liver degradation) by 13000% (patent submitted)

• Subject Matter Expert in oral thin films (strips) and buccal permeation; supported Business Development by presenting at clients and conferences
• Broad scientific knowledge in pharmaceutical chemistry
• 23 years of scientific research started as a sophomore in Chemistry (Field-flow Fractionation) honing my critical thinking, problem solving, decision making, reporting and presenting skills
• Mentor to junior scientists from Associate degree to Ph.D.

• Instrumental in the installation, qualification, and day to day operations of a new small scale R&D manufacturing suite--2-25 kg scale
• Authored numerous SOP's for manufacturing suite operations and equipment
• Managed and scaled-up numerous formulations to 15-25 kg scale
• Organized and manufactured clinical samples according to cGXP's for 7 clinical trials
• Successfully managed the scale-up of 3 formulations to 80-100 kg scale in production
• Designed and executed numerous studies on the impact of effect of excipient selection and levels, equipment, manufacturing processes, and packaging materials on the products

• Responsibilities continuously expanded from an entry level Ph.D. scientist, to complete management of cross-functional teams in complex and rapidly changing programs
• Primary contact for clients concerning all project aspects
• Mentored and managed a formulation group-the Ph.D. scientist reporting to me for promotion to my level in 1-1/2 years
• Strategic thinker responsible to develop and execute project plans
• Responsible for risk evaluation and management of lead formulations as well as root cause analysis of formulation and manufacturing process problems
• Strong collaborator with both external partners and internal departments and able to identify key issues and find options to solve problems to move projects forward

• Broad background in analytical chemistry and separation sciences
• Graduate course in separation science
• Published in Field-flow Fractionation
• Expertise in many forms of microscopy, numerous separation techniques, and spectroscopic determinations. Experience with rheometry, DMA, DSC, and laser light scattering (more info)
• Designed and executed in vitro permeation studies using artificial membranes, ex vivo animal tissue, and cell culture generated "buccal tissue"
• Experience with aseptic (BSC class 2) culturing of cells, helped design and interpret results from Pilot Pharmacokinetic Clinical Studies

• Primary responsibility for CMC section and author of all formulation aspects in numerous IMPD/IND's
• Managed the installation and qualification of a new small scale R&D manufacturing suite
• Author of numerous SOP's, batch records, stability protocols, and technical reports

Post-doctoral Fellow: Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, Utah, 2002-2003, Advisor: Jindrich Kopecek.

• Developed HPLC and fluorescent spectroscopy methods to characterize and determine the biodistribution of anticancer photosensitizer drugs
• Measured the biodistribution of anticancer photosensitizer drugs in mice
• Synthesized and characterized anticancer-polymer conjugates

Graduate Research Assistant / Ph.D. Student: Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, Utah, 1994-2002, Advisor: Jindrich Kopecek.

• Designed, synthesized, characterized, and tested a targeted water soluble polymer delivery system for antisense oligonucleotides for the treatment of hepatitis B.
• Collaborated with several groups to study the intracellular fate of TAT-polymer conjugates, doxorubicin-polymer conjugates, and an anti-AIDS/anti-CMVH compound using four different confocal microscopes in various departments.
• Authored/coauthored six articles, a dissertation, seven abstracts, as well as numerous oral presentations in university seminars, department seminars, and group meetings.

(Shortcuts to:) Six publications,  seven abstracts,  and my Ph.D. Dissertation

• Synthesized and characterized biodegradable polymers (polyanhydrides) for drug delivery.
• Produced biodegradable microparticles for the delivery of antibiotics and imaging agents.
• Coauthored a patent disclosure for biodegradable microparticles as imaging agents.

(Shortcut to:) Patent disclosure for biodegradable latexes for MRI imaging agent and drug delivery.

• First author of paper receiving the AAPS PharmSci & AAPS PharmSciTech Outstanding Use of Technology Award
• Walter F. Enz Award in Pharmaceutics from Pharmacia
• Nagai Foundation Tokyo CRS Graduate Student Award
• American Foundation of Pharmaceutical Education Pre-doctoral Fellowship
• American Foundation of Pharmaceutical Education Pre-doctoral Fellowship
• American Foundation of Pharmaceutical Education Pre-doctoral Fellowship
• NIH Biological Chemistry Training Fellowship
• Higuchi Fellowship in Pharmaceutics
• Walter D. and Grace Bonner Memorial Award in Chemistry
• Leon L. Watters Memorial Award for Achievement in Chemistry
• University of Utah Liberal Education Study Abroad Scholarship
• Leon L. Watters Memorial Award for Achievement in Chemistry
• University of Utah Chemistry Department Four-year Scholarship

Scientific, problem solving, and goal orientated

A broad and thorough knowledge and experience in pharmaceutical chemistry through developing numerous oral pharmaceutical formulations, numerous classes and research projects has honed my ability to dissect large problems into precise objectives. These were systematically employed to reach solutions and improve formulations.

Leadership, Collaboration, and Teamwork

At MIT and LTS I mentored and led up to 8 direct reports and 5 indirect reports which ranged from members having an associate's degree to a Ph.D. ranging from recent graduates to near retirement. I mentored all team members according to their status and help advance their careers. I am diplomatic being able to engage most all personalities to help them solve problems and advance the projects.

Oral and Written Communication

Authored/coauthored/presented three global patent disclosure/ applications, 8 journal articles, several CMC sections of IMPD/INDs, a Ph.D. dissertation, a Senior Honors Thesis, 11 abstracts, many SOPs, monthly reports, and numerous oral presentations to partner companies, seminars, and group meetings.

Oral Adsorption: studied the effects of a drug's biopharmaceutical properties (solubility, permeability, metabolism, and transport) on oral adsorption and pharmacokinetic modeling

In Vitro and In Vivo Methods: aseptic (class 2 containment) culturing of Hep G2 (hepatocyte) and A2780 (ovarian carcinoma) cells, minor animal operations, liver removal, and isolation of rat liver lysosomes (tritosomes)

Microscopy: confocal laser fluorescence, epi-fluorescence, brightfield, and limited use of a scanning electron microscope

Film Characterization: Basic rheometry of wet masses, DMA (Dynamic Mechanical Analyzer) of dried films, DSC (Differential Scanning Calorimetry) of drug and excipients, and size measurements by laser light scattering.

Separations: HPLC, SEC (FPLC, GPC), FFF, TLC, and PAGE

Spectroscopic Determinations: UV/vis, fluorescent spectroscopy, FTIR, and interpretation of NMR, mass spectroscopy, and elemental analysis data

Chemical Synthesis: small molecular weight and polymeric (hydrophilic and hydrophobic/biodegradable) compounds

• American Institute of Chemical Engineers (2016, active)
• Controlled Release Society (1998)
• American Association of Pharmaceutical Scientists (1996, active)
• American Chemical Society (1994)
• Phi Kappa Phi (1993)
• Phi Beta Kappa (1993)
• Delta Phi Alpha (1993)
• Sigma Xi, The Scientific Research Society (1992)
• National Honor Society (1986)
• National Forensic League (1983)

1. Regulatory Perspectives on Continuous Pharmaceutical Manufacturing: Moving from Theory to Practice. September 26-27, 2016, International Symposium on the Continuous Manufacturing of Pharmaceuticals. Moheb M. Nasr, Markus Krumme, Yoshihiro Matsuda, Bernhardt L. Trout, Clive Badman, Salvatore Mascia, Charles L. Cooney, Keith D. Jensen, Alastair Florence, Craig Johnston, Konstantin Konstantinov, Sau L. Lee. J. Pharm. Sci. 106 (11), 3199-3206 (2017). [Link]
   
   
2. End-to-End Continuous Manufacturing: Integration of Unit Operations (book chapter) in Continuous Manufacturing of Pharmaceuticals (Advances in Pharmaceutical Technology). Richard Lakerveld, Patrick L. Heider, Keith D. Jensen, Richard D. Braatz, Klavs F. Jensen, Allan S. Myerson, and Bernhardt L. Trout. Editors: P. Kleinebudde, J. Khinast, J. Rantanen. John Wiley & Sons, Hoboken, NJ, pp. 447-483. (Published on-line: 14 July, 2017). [Link to Chapter] [Link to Book]
   
   
3. Continuous Heterogeneous Crystallization on Excipient Surfaces. Nima Yazdanpanah, Christopher J. Testa, Siva R.K. Perala, Keith D. Jensen, Richard D. Braatz, Allan S. Myerson, and Bernhardt L. Trout. Crystal Growth & Design, 17 (6), 3321-3330 (2017). [Link]
   
   
4. Development of Maltodextrin-Based Immediate-Release Tablets using an Integrated Twin-Screw Hot-Melt Extrusion and Injection-Molding Continuous Manufacturing Process. Vibha Puri, David Brancazio, Parind Desai, Keith D. Jensen, Jung-Hoon Chun, Allan S. Myerson, Bernhardt L. Trout. J. Pharm. Sci. 106 (11), 3327-3336 (2017). [Link]
   
   
5. Water-soluble Placebo Polymer Thin Films for Continuous Manufacturing of Tablets. Aishuang Xiang, Hannah K. Fitch, Keith D. Jensen, Allan S. Myerson, Bernhardt L Trout. (In Preparation).
   
   
6. Integrated Hot-Melt Extrusion--Injection Molding Continuous Tablet Manufacturing Platform: Effects of Critical Process Parameters and Formulation Attributes on Product Robustness and Dimensional Stability. Parind M. Desai, Rachael C. Hogan, David Brancazio, Vibha Puri, Keith D. Jensen, Jung-Hoon Chun, Allan S. Myerson, Bernhardt L. Trout. Int. J. Pharm. 531 (1), 332-342 (2017). [Link]
   
   
7. Demonstration of Pharmaceutical Tablet Coating by Injection Molding Technology. Vibha Puri, Parind M. Desai, David Brancazio, Alexander R. Martinez, Keith D. Jensen, Eranda Harinath, Richard Braatz, Jung-Hoon Chun, Bernhardt L. Trout. (Submitted), (2017).
   
   
8. Tablet Coating by Injection Molding Technology--Optimizatin of Coating Formulation Attributes and Coating Process Parameters. Parind M. Desai, Vibha Puri, David Brancazio, Bhakti S. Halkude, Jeremy E. Hartman, Aniket V. Wahane, Alexander R. Martinez, Keith D. Jensen, Eranda Harinath, Richard Braatz, Jung-Hoon Chun, Bernhardt L. Trout. Euro. J. Pharm. and BioPharm (In-press), (2017).
   
   
9. Confocal Microscopy Studies of a Model Oligoribonucleotide HIV Inhibitor. Robyn Hyde, Keith D. Jensen, Jindrich Kopecek, and Arthur D. Broom. Nucleosides, Nucleotides, and Nucleic Acids. 24, 1875-1884 (2005). [Abstract] [Link]
   
   
10. Subcellular Trafficking of HPMA Copolymer-Tat Conjugates in Human Ovarian Carcinoma Cells. Aparna Nori, Keith D. Jensen, Monica Tijerina, Pavla Kopeckova, and Jindrich Kopecek. J of Controlled Release. 91 (1-2), 53-59 (2003). [Abstract] [Link]
    
    
11. Cytoplasmic Delivery and Nuclear Targeting of Synthetic Macromolecules. Keith D. Jensen, Aparna Nori, Monica Tijerina, Pavla Kopeckova, and Jindrich Kopecek. J Controlled Release. 87 (1-3), 89-105 (2003). [Abstract] [Link]
    
    
12. TAT-Conjugated Synthetic Macromolecules Facilitate Cytoplasmic Drug Delivery To Human Ovarian Carcinoma Cells. Aparna Nori, Keith D. Jensen, Monica Tijerina, Pavla Kopeckova, and Jindrich Kopecek. Bioconjugate Chem. 14 (1), 44-50 (2002). [Abstract] [Link]
    
    
13. Antisense Oligonucleotides Delivered to the Lysosome Escape and Actively Inhibit the Hepatitis B Virus. Keith D. Jensen, Pavla Kopeckova, and Jindrich Kopecek. Bioconjugate Chem. 13 (5), 975-984 (2002). [Abstract] [Link] (Selected as the cover article).
    
    
14. The Internalization and Fate of HPMA Copolymers and Antisense-HPMA Copolymer Conjugates in Hep G2 Cells. Keith D. Jensen. Dissertation for Ph.D. in Pharmaceutics and Pharmaceutical Chemistry, University of Utah (August 9, 2002). [Abstract]
    
    
15. The Cytoplasmic Escape and Nuclear Accumulation of Endocytosed and Microinjected HPMA Copolymers and a Basic Kinetic Study in Hep G2 Cells. Keith D. Jensen, Pavla Kopeckova, John H. B. Bridge, and Jindrich Kopecek. AAPS PharmSci, 3 (4), article 32, (2001). [Abstract] [Link]
    
    
16. The Influence of Cytotoxicity of Macromolecules and of VEGF Gene Modulated Vascular Permeability on the Enhanced Permeability and Retention Effect in Resistant Solid Tumors. Tamara Minko, Pavla Kopeckova, Vitaliy Poxharov, Keith D. Jensen, and Jindrich Kopecek. Pharm. Res., 17, 505-514 (2000). [Abstract] [Link]
    
    
17. High Speed Particle Separation and Steric Inversion in Thin Flow Field-flow Fractionation Channels. Keith D. Jensen, S. Kim R. Williams, and J. Calvin Giddings. J. of Chromatography A, 746, 137-145 (1996). [Abstract] [Link]
    
    
18. Field-flow Fractionation in the Hyperlayer Inversion Region. Keith D. Jensen. Senior Honors Thesis for the Honors Degree of Bachelor of Science in Chemistry, University of Utah, (1993). [Abstract]
    

1. Advances in Drug Development and Continuous Processing. Keith D. Jensen. Invited Oral Presentation at the Tokyo Institute of Technology, Yokohama Campus, Japan. March 12, 2019.
   
   
2. Continuous Manufacturing of Tablets via Hot-Melt Extrusion and Coupled Injection Molding. Keith D. Jensen. Invited keynote address at the International Conference on Drug Printing & Drug delivery Technology, University of Toyama, Toyama, Japan. March 15, 2019.
   
   
3. Three Strategies for Drug Delivery and Continuous Manufacturing. Keith D. Jensen. Invited oral presentation at Sichuan Univeristy, Chengdu, China. April 1, 2019.
   
   
4. Continuous Heterogeneous Crystallization and the New Method of Making Tablets. Nima Yazdanpanah, Jelena Stojakovic, Keith D. Jensen, Allan S. Myerson, and Bernhardt L. Trout. 2017 Annual Meeting of the American Institute of Chemical Engineers, Menneapolis, MN, Oct. 29 - Nov. 3, 2017, Abstract # 539d.
   
   
5. Innovations & Breakthroughs in Continuous Crystallization Processing. Keith D. Jensen. Invited Oral Presentation at the Commercializing Continuous Manufacturing in Pharma. Boston, Massachusetts, Jan. 30-Feb 1, 2017.
   
   
6. Tablet Coating by Injection Molding Technology. Parind M. Desai, Vibha Puri, David Brancazio, Alex R. Martinez, Jeremy E. Hartman, Keith D. Jensen, Eranda Harinath, Richard D. Braatz, Jung-Hoon, Chun, Allan S. Myerson, Bernhardt L Trout. 2016 Annual Meeting of the American Association of Pharmaceutical Scientists, Denver, Colorado, November 13-17, 2016, Abstract # 22W0100.
   
   
7. Dimensional Stability of Injection Molded Maltodextrin Based Griseofulvin Tablets. Parind M. Desai, Rachael C. Hogan, David Brancazio, Jeremy E. Hartman, Vibha Puri, Keith D. Jensen, Jung-Hoon, Chun, Allan S. Myerson, Bernhardt L Trout. 2016 Annual Meeting of the American Association of Pharmaceutical Scientists, Denver, Colorado, November 13-17, 2016, Abstract # 22M0200.
   
   
8. Water-soluble Placebo Polymer Thin Films for Continuous Manufacturing of Tablets. Aishuang Xiang, Keith D. Jensen, Hannah K. Fitch, Allan S. Myerson, Bernhardt L Trout. 2015 Annual Meeting of the American Association of Pharmaceutical Scientists, Orlando, Florida, October 25-29, 2015, Abstract #W5317.
   
   
9. Development of Immediate Release Tablets by Integrated Hot Melt Extrusion and Injection Molding Process Technology: A Potential Platform for Continuous Pharmaceutical Manufacturing. Vibha Puri, David Brancazio, Keith D. Jensen., Jung-Hoon Chun, Allan S. Myerson, Bernhardt L. Trout. 2015 Annual Meeting of the American Association of Pharmaceutical Scientists, Orlando, Florida, October 25-29, 2015, Abstract #M1022.
   
   
10. Continuous Heterogeneous Crystallization of Active Pharmaceutical Ingredients on Excipient Surfaces. Christopher J. Testa, Siva R. K. Perala, Keith D. Jensen, Bernahrdt L. Trout, Allan S. Myerson. 2015 Annual Meeting of the American Association of Pharmaceutical Scientists, Orlando, Florida, October 25-29, 2015, Abstract #W5295.
    
    
11. Three Aspects of Modernizing Pharmaceutical Product Manufacturing: Continuous, QbD, and PAT. Keith D. Jensen. Invited Oral Presentation at the Seventh pan-European Science Conference on QbD and PAT Sciences - Inventing Tomorrow's Development and Manufacturing. Graz, Austria, May 18-19, 2015.
    
    
12. Continuous Manufacturing and Its Implementation into the Pharmaceutical Industry: An Academic Perspective. Keith D. Jensen. Invited Oral Presentation at the 50th AAPS Arden Conference on Continuous Manufacturing of Solid Oral Drug Products, 2015. Baltimore, Maryland, March 16-18.
    
    
13. Continuous Manufacturing: The Bridge to the Future? Keith D. Jensen. Invited Oral Presentation at the strategy& Pharma Executive Roundtable 2014, Frankfurt, Germany, September 25, 2014.
    
    
14. Continuous Downstream Manufacturing via Free surface Electrospinning. Indrani Bhattacharyya, Rachael C. Hogan, Keith D. Jensen, Gregory C. Rutledge. International Symposium on Continuous Manufacturing of Pharmaceuticals, MIT, Cambridge, Massachusetts, May 20-21, 2014.
    
    
15. Advantages of Oral Thin Film Strips. Keith D. Jensen. Invited Oral Presentation at the Thirteenth Annual Drug Delivery Partnerships, Las Vegas, NV, January 21-23, 2009.
    
    
16. Cytoplasmic Delivery and Nuclear Targeting of Synthetic Macromolecules. Aparna Nori, Monica Tijerina, Keith D. Jensen, Pavla Kopeckova, and Jindrich Kopecek. Seventh European Symposium on Controlled Drug Delivery, Noordwijk ann Zee, Netherlands, April 3-5, 2002, Proceedings, p. 31. [Abstract].
    
    
17. Cytoplasmic Delivery and Nuclear Targeting of HPMA Copolymer-TAT Conjugates to Human Ovarian Carcinoma Cells. Aparna Nori, Keith D. Jensen, Pavla Kopeckova, and Jindrich Kopecek. 28th International Symposium on Controlled Release of Bioactive Materials, San Diego, California, June 23-27, 2001. Proceedings. Abstract #6122. [Abstract (186 KB PDF file)]
    
    
18. The Influence of Cytotoxicity of Macromolecules on the EPR Effect in Resistant Solid Tumors. Pavla Kopeckova, Tamara Minko, Keith D. Jensen, and Jindrich Kopecek. Fourth International Symposium on Polymer Therapeutics, London, England, January 5-7, 2000, Programme and Proceedings, p. 53. [Abstract]
    
    
19. Studying the Fate of Antisense Oligonucleotide/Polymer Conjugates Targeted to Hep G2 Cells. Keith D. Jensen, Pavla Kopeckova, and Jindrich Kopecek. 14th Annual Meeting of the American Association of Pharmaceutical Scientists, New Orleans, Louisiana. November 14-18, 1999, AAPS PharmSci 1 (4) Supplement. Abstract #4099. [Abstract]
    
    
20. Study of the Internalization and Subcellular Trafficking of Model Antisense Compounds in Hep G2 Cells. Keith D. Jensen, Pavla Kopeckova, and Jindrich Kopecek. 25th International Symposium on Controlled Release of Bioactive Materials, Las Vegas, Nevada. June 21-24, 1998, Proceedings, pp. 352-353, Abstract #5009. [Abstract (116 KB PDF file)]
    
    
21. A Hepatocyte Targeted Antisense Oligonucleotide Delivery System Using Copolymers of N-(2-Hydroxypropyl)Methacrylamide. Keith D. Jensen, Pavla Kopeckova, and Jindrich Kopecek. 12th Annual Meeting of the American Association of Pharmaceutical Scientists, Boston, Massachusetts, November 2-6, 1997, Pharm Res 14 (11 supplement), S-55, Abstract #1169. [Abstract]
    
    
22. Aspects in the Development of Polyanhydride Sustained Drug Delivery Devices. Keith D. Jensen, Peter Tarcha*, Youqin Tian*, Dennis Stephens*, H.C. Chang*, Shen Chen*, and Luk Li*. Center for Biopolymer at Interfaces Symposium, September 1996.
    *Advanced Drug Delivery Group, Hospital Products Division, Abbott Laboratories.
    
    
23. Steric Inversion and High Speed Crossflow Field-flow Fractionation Analysis. Keith D. Jensen, S. Kim Ratanathanawongs, and J. Calvin Giddings. Fifth International Symposium on Field-flow Fractionation, Park City, Utah, July 1995. [Abstract]
    
    
24. Lowering the Steric Transition Diameter and Fast Separations in Field-flow Fractionation. Keith D. Jensen, S. Kim Ratanathanawongs, and J. Calvin Giddings. Seventh National Conference on Undergraduate Research, University of Utah, Salt Lake City, Utah, April 1993. [Abstract]
    
    
25. Field-flow Fractionation of Particles in the Steric Inversion Region. Keith D. Jensen, S. Kim Ratanathanawongs, and J. Calvin Giddings. Sixth National Conference on Undergraduate Research, University of Minnesota, Minneapolis, Minnesota, April 1992, Abstract #992. [Abstract]
    
    
26. Manipulation of the Steric Transition Diameter in Flow FFF. Keith D. Jensen, S. Kim Ratanathanawongs, and J. Calvin Giddings. Third International Symposium on Field-flow Fractionation, Park City, Utah, October 1992. [Abstract]

Available upon request